Prostate stem cell antigen interacts with nicotinic acetylcholine receptors and is affected in Alzheimer's disease

Neurobiology of Aging

Volumn 36, Issue 4, 2015, Pages 1629-1638

  Jensen, Majbrit M ^a   Arvaniti, Maria ^a   Mikkelsen, Jens D ^a   Michalski, Dominik ^b   Pinborg, Lars H ^a   Härtig, Wolfgang ^b   Thomsen, Morten S ^a  

^a Rigshospitalet   (Denmark)

^b UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Alzheimer's disease; Frontal cortex; Lynx; Lypd6; Nicotinic acetylcholine receptor; PSCA

Indexed keywords

AMYLOID BETA PROTEIN; CELL PROTEIN; LYNX PROTEIN; LYPD6 PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; NICOTINIC RECEPTOR; PROSTATE STEM CELL ANTIGEN; UNCLASSIFIED DRUG; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; LY ANTIGEN; LYPD6 PROTEIN, HUMAN; PROTEIN BINDING; PSCA PROTEIN, HUMAN; TUMOR ANTIGEN; TUMOR PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; AMYLOIDOSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; FEMALE; FRONTAL CORTEX; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MALE; MIDDLE AGED; MIDDLE FRONTAL GYRUS; MOUSE; NONHUMAN; PC12 CELL LINE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TAUOPATHY; TG2576 MOUSE; VERY ELDERLY; WESTERN BLOTTING; WILD TYPE; ANIMAL; FRONTAL LOBE; GENETICS; METABOLISM; PHYSIOLOGY; RAT; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; ANIMALS; ANTIGENS, LY; ANTIGENS, NEOPLASM; COGNITION DISORDERS; FRONTAL LOBE; GPI-LINKED PROTEINS; HUMANS; MALE; MICE, TRANSGENIC; NEOPLASM PROTEINS; PC12 CELLS; PROTEIN BINDING; PROTEIN INTERACTION MAPS; RATS; RECEPTORS, NICOTINIC;

EID: 84925300368     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2015.01.001     Document Type: Article

References (60)

1. Adams J.P., Sweatt J.D. Molecular psychology: roles for the ERK MAP kinase cascade in memory. Annu. Rev. Pharmacol. Toxicol. 2002, 42:135-163.
2. Adermann K., Wattler F., Wattler S., Heine G., Meyer M., Forssmann W.G., Nehls M. Structural and phylogenetic characterization of human SLURP-1, the first secreted mammalian member of the Ly-6/uPAR protein superfamily. Protein Sci. 1999, 8:810-819.
3. Auld D.S., Kornecook T.J., Bastianetto S., Quirion R. Alzheimer's disease and the basal forebrain cholinergic system: relations to beta-amyloid peptides, cognition, and treatment strategies. Prog. Neurobiol. 2002, 68:209-245.
4. Bamezai A. Mouse Ly-6 proteins and their extended family: markers of cell differentiation and regulators of cell signaling. Arch. Immunol. Ther. Exp. (Warsz) 2004, 52:255-266.
5. Bilkei-Gorzo A. Genetic mouse models of brain ageing and Alzheimer's disease. Pharmacol. Ther. 2014, 142:244-257.
6. Braak H., Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991, 82:239-259.
7. Braak H., Braak E. Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol. Aging 1995, 16:271-278. discussion 278-284.
8. Buckingham S.D., Jones A.K., Brown L.A., Sattelle D.B. Nicotinic acetylcholine receptor signalling: roles in Alzheimer's disease and amyloid neuroprotection. Pharmacol. Rev. 2009, 61:39-61.
9. Carson R., Craig D., Hart D., Todd S., McGuinness B., Johnston J.A., O'Neill F.A., Ritchie C.W., Passmore A.P. Genetic variation in the alpha 7 nicotinic acetylcholine receptor is associated with delusional symptoms in Alzheimer's disease. Neuromolecular Med. 2008, 10:377-384.
10. Carson R., Craig D., McGuinness B., Johnston J.A., O'Neill F.A., Passmore A.P., Ritchie C.W. Alpha7 nicotinic acetylcholine receptor gene and reduced risk of Alzheimer's disease. J.Med. Genet. 2008, 45:244-248.
11. Cook L.J., Ho L.W., Taylor A.E., Brayne C., Evans J.G., Xuereb J., Cairns N.J., Pritchard A., Lemmon H., Mann D., St Clair D., Turic D., Hollingworth P., Moore P.J., Jehu L., Archer N., Walter S., Foy C., Edmondson A., Powell J., Lovestone S., Owen M.J., Williams J., Lendon C., Rubinsztein D.C. Candidate gene association studies of the alpha 4 (CHRNA4) and beta 2 (CHRNB2) neuronal nicotinic acetylcholine receptor subunit genes in Alzheimer's disease. Neurosci. Lett. 2004, 358:142-146.
12. Court J., Martin-Ruiz C., Piggott M., Spurden D., Griffiths M., Perry E. Nicotinic receptor abnormalities in Alzheimer's disease. Biol. Psychiatry 2001, 49:175-184.
13. Darvas M., Morsch M., Racz I., Ahmadi S., Swandulla D., Zimmer A. Modulation of the Ca2+ conductance of nicotinic acetylcholine receptors by Lypd6. Eur. Neuropsychopharmacol. 2009, 19:670-681.
14. Davies A., Simmons D.L., Hale G., Harrison R.A., Tighe H., Lachmann P.J., Waldmann H. CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells. J.Exp. Med. 1989, 170:637-654.
15. Davies P., Feisullin S. Postmortem stability of alpha-bungarotoxin binding sites in mouse and human brain. Brain Res. 1981, 216:449-454.
16. Dorszewska J., Florczak J., Rozycka A., Jaroszewska-Kolecka J., Trzeciak W.H., Kozubski W. Polymorphisms of the CHRNA4 gene encoding the alpha4 subunit of nicotinic acetylcholine receptor as related to the oxidative DNA damage and the level of apoptotic proteins in lymphocytes of the patients with Alzheimer's disease. DNA Cell Biol. 2005, 24:786-794.
17. Dubois B., Feldman H.H., Jacova C., Dekosky S.T., Barberger-Gateau P., Cummings J., Delacourte A., Galasko D., Gauthier S., Jicha G., Meguro K., O'Brien J., Pasquier F., Robert P., Rossor M., Salloway S., Stern Y., Visser P.J., Scheltens P. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007, 6:734-746.
18. El Kouhen R., Hu M., Anderson D.J., Li J., Gopalakrishnan M. Pharmacology of alpha7 nicotinic acetylcholine receptor mediated extracellular signal-regulated kinase signalling in PC12 cells. Br. J. Pharmacol. 2009, 156:638-648.
19. Fritz B.A., Lowe A.W. Polarized GP2 secretion in MDCK cells via GPI targeting and apical membrane-restricted proteolysis. Am. J. Physiol. 1996, 270:176-183.
20. Gubbins E.J., Gopalakrishnan M., Li J. Alpha7 nAChR-mediated activation of MAP kinase pathways in PC12 cells. Brain Res. 2010, 1328:1-11.
21. Härtig W., Saul A., Kacza J., Grosche J., Goldhammer S., Michalski D., Wirths O. Immunolesion-induced loss of cholinergic projection neurones promotes beta-amyloidosis and tau hyperphosphorylation in the hippocampus of triple-transgenic mice. Neuropathol. Appl. Neurobiol. 2014, 40:106-120.
22. Hellstrom-Lindahl E., Mousavi M., Zhang X., Ravid R., Nordberg A. Regional distribution of nicotinic receptor subunit mRNAs in human brain: comparison between Alzheimer and normal brain. Brain Res. Mol. Brain Res. 1999, 66:94-103.
23. Hruska M., Keefe J., Wert D., Tekinay A.B., Hulce J.J., Ibanez-Tallon I., Nishi R. Prostate stem cell antigen is an endogenous lynx1-like prototoxin that antagonizes alpha7-containing nicotinic receptors and prevents programmed cell death of parasympathetic neurons. J.Neurosci. 2009, 29:14847-14854.
24. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F., Cole G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 1996, 274:99-102.
25. Ibanez-Tallon I., Miwa J.M., Wang H.L., Adams N.C., Crabtree G.W., Sine S.M., Heintz N. Novel modulation of neuronal nicotinic acetylcholine receptors by association with the endogenous prototoxin lynx1. Neuron 2002, 33:893-903.
26. Jurgensen S., Ferreira S.T. Nicotinic receptors, amyloid-beta, and synaptic failure in Alzheimer's disease. J.Mol. Neurosci. 2010, 40:221-229.
27. Kawamata J., Shimohama S. Association of novel and established polymorphisms in neuronal nicotinic acetylcholine receptors with sporadic Alzheimer's disease. J.Alzheimers Dis. 2002, 4:71-76.
28. Kendziorra K., Wolf H., Meyer P.M., Barthel H., Hesse S., Becker G.A., Luthardt J., Schildan A., Patt M., Sorger D., Seese A., Gertz H.J., Sabri O. Decreased cerebral alpha4beta2* nicotinic acetylcholine receptor availability in patients with mild cognitive impairment and Alzheimer's disease assessed with positron emission tomography. Eur. J. Nucl. Med. Mol. Imaging 2011, 38:515-525.
29. Laumet G., Chouraki V., Grenier-Boley B., Legry V., Heath S., Zelenika D., Fievet N., Hannequin D., Delepine M., Pasquier F., Hanon O., Brice A., Epelbaum J., Berr C., Dartigues J.F., Tzourio C., Campion D., Lathrop M., Bertram L., Amouyel P., Lambert J.C. Systematic analysis of candidate genes for Alzheimer's disease in a French, genome-wide association study. J.Alzheimers Dis. 2010, 20:1181-1188.
30. Laursen B., Mork A., Plath N., Kristiansen U., Bastlund J.F. Impaired hippocampal acetylcholine release parallels spatial memory deficits in Tg2576 mice subjected to basal forebrain cholinergic degeneration. Brain Res. 2014, 1543:253-262.
31. Lee J.E., Han P.L. An update of animal models of Alzheimer disease with a reevaluation of plaque depositions. Exp. Neurobiol. 2013, 22:84-95.
32. Lyukmanova E.N., Shenkarev Z.O., Shulepko M.A., Mineev K.S., D'Hoedt D., Kasheverov I.E., Filkin S.Y., Krivolapova A.P., Janickova H., Dolezal V., Dolgikh D.A., Arseniev A.S., Bertrand D., Tsetlin V.I., Kirpichnikov M.P. NMR structure and action on nicotinic acetylcholine receptors of water-soluble domain of human LYNX1. J.Biol. Chem. 2011, 286:10618-10627.
33. Marutle A., Gillberg P.G., Bergfors A., Yu W., Ni R., Nennesmo I., Voytenko L., Nordberg A. (3)H-deprenyl and (3)H-PIB autoradiography show different laminar distributions of astroglia and fibrillar beta-amyloid in Alzheimer brain. J.Neuroinflammation 2013, 10:90.
34. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34:939-944.
35. Meri S., Lehto T., Sutton C.W., Tyynela J., Baumann M. Structural composition and functional characterization of soluble CD59: heterogeneity of the oligosaccharide and glycophosphoinositol (GPI) anchor revealed by laser-desorption mass spectrometric analysis. Biochem. J. 1996, 316(Pt 3):923-935.
36. Miwa J.M., Freedman R., Lester H.A. Neural systems governed by nicotinic acetylcholine receptors: emerging hypotheses. Neuron 2011, 70:20-33.
37. Miwa J.M., Stevens T.R., King S.L., Caldarone B.J., Ibanez-Tallon I., Xiao C., Fitzsimonds R.M., Pavlides C., Lester H.A., Picciotto M.R., Heintz N. The prototoxin lynx1 acts on nicotinic acetylcholine receptors to balance neuronal activity and survival invivo. Neuron 2006, 51:587-600.
38. Miwa J.M., Walz A. Enhancement in motor learning through genetic manipulation of the Lynx1 gene. PLoS One 2012, 7:e43302.
39. Morishita H., Miwa J.M., Heintz N., Hensch T.K. Lynx1, a cholinergic brake, limits plasticity in adult visual cortex. Science 2010, 330:1238-1240.
40. Nakayama H., Shimoke K., Isosaki M., Satoh H., Yoshizumi M., Ikeuchi T. Subtypes of neuronal nicotinic acetylcholine receptors involved in nicotine-induced phosphorylation of extracellular signal-regulated protein kinase in PC12h cells. Neurosci. Lett. 2006, 392:101-104.
41. Nery A.A., Magdesian M.H., Trujillo C.A., Sathler L.B., Juliano M.A., Juliano L., Ulrich H., Ferreira S.T. Rescue of amyloid-beta-induced inhibition of nicotinic acetylcholine receptors by a peptide homologous to the nicotine binding domain of the alpha 7 subtype. PLoS One 2013, 8:e67194.
42. Nordberg A., Lundqvist H., Hartvig P., Lilja A., Langstrom B. Kinetic analysis of regional (S)(-)11C-nicotine binding in normal and Alzheimer brains-invivo assessment using positron emission tomography. Alzheimer Dis. Assoc. Disord. 1995, 9:21-27.
43. Oddo S., Caccamo A., Shepherd J.D., Murphy M.P., Golde T.E., Kayed R., Metherate R., Mattson M.P., Akbari Y., LaFerla F.M. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular abeta and synaptic dysfunction. Neuron 2003, 39:409-421.
44. Okada H., Ouchi Y., Ogawa M., Futatsubashi M., Saito Y., Yoshikawa E., Terada T., Oboshi Y., Tsukada H., Ueki T., Watanabe M., Yamashita T., Magata Y. Alterations in alpha4beta2 nicotinic receptors in cognitive decline in Alzheimer's aetiopathology. Brain 2013, 136:3004-3017.
45. Perry E., Martin-Ruiz C., Lee M., Griffiths M., Johnson M., Piggott M., Haroutunian V., Buxbaum J.D., Nasland J., Davis K., Gotti C., Clementi F., Tzartos S., Cohen O., Soreq H., Jaros E., Perry R., Ballard C., McKeith I., Court J. Nicotinic receptor subtypes in human brain ageing, Alzheimer and Lewy body diseases. Eur. J. Pharmacol. 2000, 393:215-222.
46. Querfurth H.W., LaFerla F.M. Alzheimer's disease. N.Engl. J. Med. 2010, 362:329-344.
47. Reiter R.E., Gu Z., Watabe T., Thomas G., Szigeti K., Davis E., Wahl M., Nisitani S., Yamashiro J., Le Beau M.M., Loda M., Witte O.N. Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:1735-1740.
48. Sarter M., Parikh V., Howe W.M. nAChR agonist-induced cognition enhancement: integration of cognitive and neuronal mechanisms. Biochem. Pharmacol. 2009, 78:658-667.
49. Schmittgen T.D., Livak K.J. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 2008, 3:1101-1108.
50. Schnell S.A., Staines W.A., Wessendorf M.W. Reduction of lipofuscin-like autofluorescence in fluorescently labeled tissue. J.Histochem. Cytochem. 1999, 47:719-730.
51. Tekinay A.B., Nong Y., Miwa J.M., Lieberam I., Ibanez-Tallon I., Greengard P., Heintz N. Arole for LYNX2 in anxiety-related behavior. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:4477-4482.
52. Thomsen M.S., Cinar B., Jensen M.M., Lyukmanova E.N., Shulepko M.A., Tsetlin V., Klein A.B., Mikkelsen J.D. Expression of the Ly-6 family proteins Lynx1 and Ly6H in the rat brain is compartmentalized, cell-type specific, and developmentally regulated. Brain Struct. Funct. 2014, 219:1923-1934.
53. Thomsen M.S., Hansen H.H., Timmerman D.B., Mikkelsen J.D. Cognitive improvement by activation of alpha7 nicotinic acetylcholine receptors: from animal models to human pathophysiology. Curr. Pharm. Des. 2010, 16:323-343.
54. Thomsen M.S., Jensen M.M., Cinar B., Wang H., Gondré-Lewis M.C., Klein A.B., Mikkelsen J.D. Perinatal Nicotine Administration Increases Hippocampal Lypd6 Levels in Adulthood Program No. 702.09. 2013 Neuroscience Meeting Planner 2013, Society for Neuroscience, San Diego, CA, Online.
55. Thomsen M.S., Mikkelsen J.D. The alpha7 nicotinic acetylcholine receptor complex: one, two or multiple drug targets?. Curr. Drug Targets 2012, 13:707-720.
56. Tsetlin V. Snake venom alpha-neurotoxins and other 'three-finger' proteins. Eur. J. Biochem. 1999, 264:281-286.
57. Wang H.Y., Lee D.H., Davis C.B., Shank R.P. Amyloid peptide abeta(1-42) binds selectively and with picomolar affinity to alpha7 nicotinic acetylcholine receptors. J.Neurochem. 2000, 75:1155-1161.
58. Winton M.J., Lee E.B., Sun E., Wong M.M., Leight S., Zhang B., Trojanowski J.Q., Lee V.M. Intraneuronal APP, not free abeta peptides in 3xTg-AD mice: implications for tau versus abeta-mediated Alzheimer neurodegeneration. J.Neurosci. 2011, 31:7691-7699.
59. Yang L.B., Li R., Meri S., Rogers J., Shen Y. Deficiency of complement defense protein CD59 may contribute to neurodegeneration in Alzheimer's disease. J.Neurosci. 2000, 20:7505-7509.
60. Zhang Y., Lang Q., Li J., Xie F., Wan B., Yu L. Identification and characterization of human LYPD6, a new member of the Ly-6 superfamily. Mol. Biol. Rep. 2010, 37:2055-2062.